Ovid currently has several ongoing corporate partnerships:
In January 2017, Takeda and Ovid began an innovative clinical development and commercialization collaboration partnership to develop OV935/TAK-935 (soticlestat), a highly selective first-in-class CH24H inhibitor with the potential to reduce seizure susceptibility and improve seizure control in rare developmental and epileptic encephalopathies (DEE). As part of this agreement, Ovid leads clinical development activities and commercialization in the United States, Europe, Canada and Israel. Takeda will lead commercialization in Japan, and has the option to lead in Asia and other selected geographies.
Read Ovid press release »
Read Takeda press release »